Newsletter subscription & archive

Open call for proposals: Cell-based assays


The National Phenotypic Screening Centre in the UK is looking for cell-based assays to fund.

The National Phenotypic Screening Centre is seeking novel cell-based assays for the Phenomics Discovery Initiative (PDi). Academics, clinicians and SMEs (from anywhere in the world) can submit disease-relevant cell-based assay proposals to be developed and screened free of charge against an industry-standard small molecule compound collection.

Current areas of biology where the centre is recruiting novel assays:

  • Solid tumour model showing Immune Exclusion
  • Expanding the Immuno-Oncology Toolbox with next-generation Small Molecule Therapeutics
  • Tissue Regeneration & Repair assays
  • Neurodegeneration
  • Regulatory T cell (Treg) assays
  • Cellular stress assays
  • Human bronchoepithelial cell air-liquid assays
  • Innovative phenotypic assays - Blue Sky

If you think you have an innovative cell-based assay please visit the website to find out more and to apply.

  • The application form is short & straightforward
  • Next round of project selections is 31st October 2018
  • Selected proposals are validated and screened free of charge

Deliverables and potential screening outputs

  • A validated phenotypic assay that can be further exploited
  • Validated hits from a diversity set - specific chemical tools that may perturb the biological system reversibly or start-points for drug development
  • Validated hits from an annotated set - may illuminate mechanism and potentially even identify targets
  • Opportunities to obtain follow-on funding
  • Interactions with big pharma and potential for long-term collaboration

We cover the following costs:

  • Assay development
  • Reagents including cell lines and tissue culture
  • Access to industry standard compound collections
  • Access to world class high-content screening facilities
  • State of the art chemo- and bioinformatics.

The terms & conditions are very favourable for academics, clinicians or SMEs – if your assay is selected for screening by PDi, you own all of the results to exploit as you please (to publish, use the preliminary data for grants or to support commercial activities). There is even a possibility of a cash payment if the pharma partner deems the assay fit for purpose.

Please forward this information on to anyone you think may be able to benefit from this opportunity.

The National Phenotypic Screening Centre (NPSC) is a new world-class research facility which is located in the Universities of Oxford, Edinburgh and Dundee, three of the UK's leading academic institutions.

What are you looking for?
By using this website, you agree to the use of cookies to give you the best user experience.
Find additional information at Cookies